Accuray (NASDAQ:ARAY) posted its quarterly earnings data on Thursday. The medical equipment provider reported ($0.01) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.02) by $0.01, RTT News reports. The firm had revenue of $113.79 million during the quarter, compared to the consensus estimate of $108.45 million. Accuray had a negative return on equity of 52.91% and a negative net margin of 7.00%. During the same period in the prior year, the business earned ($0.04) EPS.

ARAY opened at $3.87 on Friday. The company has a quick ratio of 0.97, a current ratio of 1.62 and a debt-to-equity ratio of 3.00. The company has a market cap of $329.71 million, a price-to-earnings ratio of -10.42 and a beta of 1.64. Accuray has a 52 week low of $3.20 and a 52 week high of $6.15.

Several research firms have commented on ARAY. BidaskClub downgraded Accuray from a “sell” rating to a “strong sell” rating in a research note on Friday. Citigroup reduced their price objective on Accuray from $4.00 to $3.50 and set a “sell” rating for the company in a research note on Friday. ValuEngine raised Accuray from a “sell” rating to a “hold” rating in a research note on Friday, May 18th. Finally, Zacks Investment Research raised Accuray from a “strong sell” rating to a “hold” rating in a research note on Tuesday, July 3rd. Three research analysts have rated the stock with a sell rating, four have given a hold rating and three have issued a buy rating to the company’s stock. The stock currently has an average rating of “Hold” and a consensus target price of $6.68.

In other Accuray news, CEO Joshua Levine sold 34,235 shares of the company’s stock in a transaction that occurred on Tuesday, July 3rd. The stock was sold at an average price of $4.08, for a total transaction of $139,678.80. Following the completion of the sale, the chief executive officer now directly owns 1,392,518 shares of the company’s stock, valued at approximately $5,681,473.44. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CFO Kevin Waters sold 14,265 shares of the company’s stock in a transaction that occurred on Tuesday, July 3rd. The shares were sold at an average price of $4.08, for a total value of $58,201.20. Following the sale, the chief financial officer now directly owns 313,995 shares of the company’s stock, valued at $1,281,099.60. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 57,059 shares of company stock valued at $232,801. 3.90% of the stock is owned by company insiders.

About Accuray

Accuray Incorporated designs, develops, and sells radiosurgery and radiation therapy systems for the treatment of tumors in the body. The company offers the CyberKnife System, a robotic stereotactic radiosurgery and stereotactic body radiation therapy system used for the treatment of various types of cancer and tumors in the body.

Further Reading: Using the New Google Finance Tool

Earnings History for Accuray (NASDAQ:ARAY)

Receive News & Ratings for Accuray Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Accuray and related companies with MarketBeat.com's FREE daily email newsletter.